Recursion Pharmaceuticals Statistics
Total Valuation
RXRX has a market cap or net worth of $2.00 billion. The enterprise value is $1.33 billion.
Important Dates
The next estimated earnings date is Tuesday, May 5, 2026, before market open.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RXRX has 528.20 million shares outstanding. The number of shares has increased by 63.18% in one year.
| Current Share Class | 521.95M |
| Shares Outstanding | 528.20M |
| Shares Change (YoY) | +63.18% |
| Shares Change (QoQ) | +17.84% |
| Owned by Insiders (%) | 3.06% |
| Owned by Institutions (%) | 63.79% |
| Float | 511.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.74 |
| Forward PS | 23.42 |
| PB Ratio | 1.77 |
| P/TBV Ratio | 3.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.50, with a Debt / Equity ratio of 0.07.
| Current Ratio | 5.50 |
| Quick Ratio | 5.20 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -358.08 |
Financial Efficiency
Return on equity (ROE) is -59.54% and return on invested capital (ROIC) is -34.44%.
| Return on Equity (ROE) | -59.54% |
| Return on Assets (ROA) | -27.72% |
| Return on Invested Capital (ROIC) | -34.44% |
| Return on Capital Employed (ROCE) | -48.86% |
| Weighted Average Cost of Capital (WACC) | 9.53% |
| Revenue Per Employee | $124,468 |
| Profits Per Employee | -$1.07M |
| Employee Count | 600 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -136,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.95% in the last 52 weeks. The beta is 1.01, so RXRX's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | -28.95% |
| 50-Day Moving Average | 3.45 |
| 200-Day Moving Average | 4.62 |
| Relative Strength Index (RSI) | 63.07 |
| Average Volume (20 Days) | 12,810,502 |
Short Selling Information
The latest short interest is 173.93 million, so 32.93% of the outstanding shares have been sold short.
| Short Interest | 173.93M |
| Short Previous Month | 174.14M |
| Short % of Shares Out | 32.93% |
| Short % of Float | 34.03% |
| Short Ratio (days to cover) | 12.36 |
Income Statement
In the last 12 months, RXRX had revenue of $74.68 million and -$644.76 million in losses. Loss per share was -$1.44.
| Revenue | 74.68M |
| Gross Profit | -471.54M |
| Operating Income | -648.13M |
| Pretax Income | -644.90M |
| Net Income | -644.76M |
| EBITDA | -564.43M |
| EBIT | -648.13M |
| Loss Per Share | -$1.44 |
Full Income StatementBalance Sheet
The company has $743.29 million in cash and $77.97 million in debt, with a net cash position of $665.33 million or $1.26 per share.
| Cash & Cash Equivalents | 743.29M |
| Total Debt | 77.97M |
| Net Cash | 665.33M |
| Net Cash Per Share | $1.26 |
| Equity (Book Value) | 1.13B |
| Book Value Per Share | 2.14 |
| Working Capital | 665.14M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$371.81 million and capital expenditures -$6.47 million, giving a free cash flow of -$378.28 million.
| Operating Cash Flow | -371.81M |
| Capital Expenditures | -6.47M |
| Depreciation & Amortization | 83.70M |
| Net Borrowing | -8.43M |
| Free Cash Flow | -378.28M |
| FCF Per Share | -$0.72 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -867.87% |
| Pretax Margin | -863.53% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -63.18% |
| Shareholder Yield | -63.18% |
| Earnings Yield | -32.29% |
| FCF Yield | -18.95% |
Analyst Forecast
The average price target for RXRX is $7.50, which is 98.41% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.50 |
| Price Target Difference | 98.41% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RXRX has an Altman Z-Score of 1.34 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.34 |
| Piotroski F-Score | 3 |
